Ameloblastoma is an odontogenic tumor that usually occurs in the mandibl e. It is an agg ressive but benign tumor of epithelial origin that is rarely metastati c. We report the case of a 53-year-old woman who had a massive ameloblastoma of the mandible. The tumor measured 15.2 x 11.4 x 12.0 em. The patient had oral bleeding that required a transfu sion. The workup includ ed threedimensional imaging, arteriography, and embolization to control bleeding. Surgical management entailed the resection of the entire left mandible and right symphysis, fo llowed by reconstruction with afreefibularflap. To our knowledge, this is the largest reported ameloblas toma managed with three-dimensional imaging, radical resection, and free-flap reconstruction. This article also reviews aspects of the differential diagnosis, pathology, and management ofjaw tumors.
History. Guzack in 1826 and Broc a in 1868 recorded similar lesion s in the literature , but it was not until 1879 that Fallson pro vided a thorough description of an ameloblastom a. The lesion was furth er described in 1885 by Malassez, who called it an adamantinoma. The term ameloblastoma was coined by Ivy and Churchill in 1934. 4 ,5 The term giant ameloblastoma should be reserved for lesions that are truly large and that cause gross asymmetry and regional dysfunct ion.
Origin and histology. Ameloblastom a can origin ate in the dent al lamina (or its derivatives, such as epithelial rests), in the epithelial lining of odontogenic cysts, in basal cells of the surface epithelium, and in epithelium of the enamel organ." The histologic picture of ameloblastoma invol ves the palisading columnar ameloblastic cells at the periphery, with nuclei polarized awa y from the basal membrane (reverse polarization ). Loo se, stellate, reticulum-like cells inhabit epithelial islands, which can be found within a fibrous stroma (follicular pattern ). Islands of mature fibrous stroma can also be found intermingled with strands of epithelium (plexiform pattern ). In both patterns, the outermo st cells resemble those of the amelobl astic layer and the inner enamel epithelium. Histologic variations within the epith elial islands giverise to histolog ic subclasses (e.g., cystic, acanthomatous, granular cell, basal cell , and hemangiom atous).?
Case report
A thin , frail, 53-year-old woman was admitted to the hospital with a 6-year history of a gro wing mass in her left jaw (figure 1). She had experienced hemorrha ging in the oral cavity, and a foul-smelling drainage exuded from cutaneous fistulae in the left submental area. She had a cantaloupe-sized mass of the left mandible, a necrotic cavity in the left floo r of the mouth, and two drainin g fistulae in the left submental area. The wom an had been eva luated 6 years earlier for an enlarg ing jaw mass, and a biopsy at that time revealed an ameloblastom a. She had Sounds like a major advance in treatment . The following treatment-related adverse events occurred in 1% or more of the subjects with non-intact tympanic membranes.
of 810 mgikg /day. Ofloxacin has not been shown to be teratogenic at doses as high as 8 10 mgikg/day and 160 mgikg/day when administered to pregnant rats and rabbits, respectively.
Ofloxacin has not been shown to have any adverse effects on the developing embryo or fetus at doses relevant to the amount of ofioxacin that will be delivered ototopically at the recommended clinical doses.
No nteratogenic Effects :
Additional studies in the rat demonstrated that doses up to 360 mgikg/day during late gestation had no adverse effects on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the newborn. There are, however, no adequate and well-controlled studies in pregnant women. FLOXIN'" Otic should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothe rs : In nursing women, a single 200 mg oral dose resulted in concen trations of ofloxacin in milk which were similar to those found in plasma. It is not known whethe r ofloxacin is excreted in human milk following topical otic administration. Because of the potential for serious adverse reactions from ofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Ped iatr ic Use : No changes in hearing function occu rred in 30 pediatric subjects treated with ofloxacin otic and tested for audiometric parameters . Although safety and efficacy have been demonstrated in pediatric patients one year and older, safety and effectiveness in infants below the age of one year have not been established. Although quinolones, including otloxacin, have been shown to cause arthropathy in immature animals after systemic administration, young growing guinea pigs dosed in the middle ear with 0.3% otloxacin otic solution for one month showed no systemic effects, quinolone-induced lesions, erosions of the cartilage in weightbearing joints, or other signs of arthropathy.
ADVERSE REACTIONS
In the Phase III registration trials, a total of 885 subjects were treated with ofloxacin otic solution. This included 229 subjects with otitis externa (with intact tympanic membranes) and 656 subjects with acute otitis media with tympanostomy tubes or chronic suppurative otitis media with perforated tympanic membranes. The reported treatment-related adverse events are listed below:
Subiects with Otitis Externa
Thefollowlnq treatment-related adverse events occurred in 1% or more of the subjects with intact tympanic membranes.
Other treatment-related adverse reactions reported in subjects with non-intact tympanic mem- . . The systemic administration of quinolones, Including otloxacln at doses much higher than given or absorbed by the otic route, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species.
Young growing guinea pigs dosed in the middle ear 0 ith 0.3% ofloxacin otic solution showed no systemic effects, lesions or erosions of the cartilage,in weight-bearing joints, or other signs of arthropathy. No drug-related structural or functional changes of the cochlea and no lesions in the ossicles were noted in the guinea pig following otic administration of 0.3% ofloxacin for one month. \ No signs of local irritation were found when 0.3% ofloxacin was applied topically in the rabbit eye. Ofloxacin was also shown to lack dermal sensitizing potential in the guinea pig maximization study. \ Inform ation for Pati ents : Avoid contaminating the applicato/ \tip with material from the fingers or other sources. This precaution is necessary if the sterility of the drops is to be preserved. Systemic quinolones, including otloxacin, have been associated with hypersensitivity reactions, even following a single dose. Discontinue use immediateiy and contact your physician at the first sign of a rash or allergic reaction. Dru g Interac tio ns : Specific drug interaction studies have not been conducted with FLOXIN'" Otic.
Otitis Externa

Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies to determine the carcinogenic potential of ofloxacin have not been conducted. Ofloxacin was not mutagenic in the Ames test, the sister chromatid exchange assay (Chinese hamster and human cell lines), the unscheduled DNA synthesis (UDS) assay using human fibroblasts, the dominant lethal assay, or the mouse micro-nucleus assay. Ofloxacin was positive in the rat hepatocyte UDS assay, and in the mouse lymphoma assay. In rats, ofloxacin did not affect male or female reproductive performance at oral doses up to 360 mgikg/day. This would be over 1000 times the maximu m recommended clinical dose, based upon body surface area, assuming total absorption of ofloxacin from the ear of a patient treated with FLOXIN" Otic twice per day. Preg nancy Terat oge nic effe cts : Pregn ancy Catego ry C. Ofloxacin has been shown to have an embryooidal effect in rats at a dose of 810 mgikg/day and in rabbits at 160 mgikg/day.
These dosages resulted in decreased fetai body weights and increased fetal mortality in rats and rabbits, respectively. Minor fetal skeletal variations were reported in rats receiving doses been offered surgical excision then, but she refused.
In the months leading up to this latest hospitalization, the woman had been unable to maintain adequate nutrition becau se of the size of the mass . She sought medic al care only after the bleed ing from her oral cavity had become uncontrollable. On admission, the patient was anemic (hematocrit: 22), hypophosphatemic (1.6), and hypoproteinemic (protein: 3.4 ; albumin: 1.6). She required a 4-unit tran sfusion of packed red blood cells to stabilize her hematocrit at a level of 28. Three-dimensional computed tomography (CT) showed that the large mass involved the entire left mandible and obliterated the temporomandibular joint (figure 2) . Multiple central areas of hypo density were consistent with multicystic ameloblastoma. Arteriography was performed to determine the source of the tumor's vascular supply, and the mass was embolized with fibrin glue to control bleeding.
Several day s after admission, the patient was taken to the operating room for a complete resection of the mass and a percutaneous gastrostomy . After nasotracheal intubation, the mass was resected by dividing the mand ible at the symphysis, free ing the tumor from the floor of the 570 Figure 2 . Three-dimensional CT revealed that the large mass involved the entire left mandible and obliterated the temporomandibular joint.
mouth , and dissecting to the area of the previously existing temporomandibular joint. The most difficult aspect s of dissection were the freeing of the mass from the area of the glenoid fossa and the sparing of blood vessel s at the HUGHES, WILSON, OLDING base of the skull. Ivy loops were placed on the right to achieve dental occlusion, and the skin and mucosa were then reapproximated loosely. Histologic examination identified the ameloblastoma as being of the plexiform type ( figure 3) . The tumor measured 15.2 x 11.4 x 12.0 cm and weighed 1.28 kg ( figure 4) .
The second-stage reconstruction with a free fibula flap was performed 68 days after the initial procedure. The interval between the two procedures provided sufficient time for the patient to gain weight and for her medical condition to improve. Pathologic examination conducted during the first-stage operation revealed a positive margin at the mandibular symphysis, and a further 1.5 cm of the right parasymphyseal bone was resected during the freeflap reconstruction. The patient recovered from both procedures without complications. Subsequent followup revealed that the patient was doing well. Six weeks after the second procedure, she had gained weight and was pleased with the result. A third procedure, a scar revision, was performed without complication at 6 months, with a good result (figure 5). In the 2 years that followed the scar revision, the patient continued to do well, was very pleased with the final result, and had no evidence of recurrence.
Discussion
Although giant ameloblastoma is rare in developed societies, it can occur in patients who delay treatment because they fear surgery, as was the case in this patient. Even though she had been incapacitated by her disease, it still required many discussions to convince her of the need for resection. She had not been able to maintain her nutritional status, and she had experienced significant weight loss, hypoproteinemia, and anemia.
Five previous cases of ameloblastoma with secondary hypoproteinemia have been It is hypothesized that protein leakage occurs in the cyst that eventually causes the condition." Our patient was also malnourished because the size of her lesion impaired her ability to eat; this could account for the finding of hypoproteinemia. Her anemia was most likely caused by chronic bleeding. Her hypophosphatemia with relative hypercalcemia can be explained by chronic osteolysis and resorption of bone. These abnormalities resolved with improved nutrition Fits most adult mouths with no custom fitting or molding.
S Y M P T O M RELIEF not iust another referral
The TMJ Appliance@ is a computer designed, pre-molded, dental splint, specifically developed for treating TMJD in the medical practice.
The patient takes it out of the container, places it in their mouth and an IMMEDIATE decrease in symptoms usually occurs.
SNORER VERSION
The majority of intra oral snoring devices tend to be contraindicated in TMJD cases as they hold the condyles in a fixed position which is hard on the joints. This can precipitate a TMJ/D acute phase. The TMJ Appliance@ 'Snorer Version' has a 8mm hole in the front to treat selected snoring and sleep disorders in conjunction with TMJD treatment and prevention. d e s i g n e r s a n d m a n u f a c t u r e r s o f i n n o v a t i v e d e n t a l a p p l i a n c e Quality Refurbished Equipment tio n-resistant , althoug h more rece nt rep orts sug gest some success with megavoltage irradiation!" an d with co mbin ed chemo thera py and radiation.v -" Cauti on sho uld be exercised, howe ver , because histolog ic tran sfo rm ation ca n occur. A history of radi ation exp osure has been repo rted in patient s who we re diagno sed with ame loblastic carc inomas . Lifelon g followup is mandator y in these patient s, regardle ss of the treatm ent option. Recurrence rates are high , es pec ially in patients with inadequately resect ed tumo rs.
